---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-020445"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2021-08-17T23:59:59+00:00"
generated_at: "2026-06-29T09:34:54.870390+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biotricity Q1 revenue $1.76M, up 290% YoY, 9th consecutive triple-digit growth quarter

## Summary
- Revenue $1.76M for Q1 FY2022, up 290% vs. Q1 FY2021; sequential growth 49%.
- Operating expenses $4.2M, up only 17% YoY; R&D spend $590K, up 39%.
- Company projects continued revenue growth into FY2023; awaiting FDA approval for Biotres holter product.
- Gross margin or net income figures not disclosed; Company remains early-stage.

## SEC filing metadata
- accession: 0001493152-21-020445
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2021-08-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315221020445/0001493152-21-020445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315221020445/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-020445
- JSON: https://secwatch.observer/filing/0001493152-21-020445.json
- Plain text: https://secwatch.observer/filing/0001493152-21-020445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.